The federal government recently capped insulin prices at $35 a month for Medicare Part D, and drugmakers that increase insulin costs faster than inflation rates can be hit with tax penalties. Dr. Rose said these efforts are “welcome news” but come with a catch for the 37 million Americans with Type 2 diabetes.
“Of all diabetes medications, insulin carries the highest risk of causing dangerously low blood sugar,” Dr. Rose wrote. “Although insulin is excellent at tamping down high blood sugar — the hallmark of diabetes and the driver of some of its complications — it is not as impressive as other medications at mitigating the most deadly and debilitating consequences of the disease: heart attacks, kidney disease and heart failure.”
Because insulin prices and efficacy levels are decreasing, “doctors are forced daily to decide between the best medication for our patients and the medication that our patients can afford,” Dr. Rose wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.